Clinical trial • Phase I • Oncology

TG4070 for Non-small cell lung cancer | Non-small cell lung cancer stage III

Phase I trial of TG4070 for Non-small cell lung cancer | Non-small cell lung cancer stage III. 40 participants.

Overview

Trial Therapeutic Area
Oncology
Trial Disease
Non-small cell lung cancer | Non-small cell lung cancer stage III
Trial Stage
Phase I
Drug Modality
Vaccine

Key dates

Initial CTIS Submission Date
05-03-2025
First CTIS Authorization Date
15-07-2025

Trial design

Phase I trial across 5 sites in France.

Target Sample Size
40

Recruitment

Planned Sample Size
40
Recruitment Window Months
84

Geography

Total Number Of Sites
5
Total Number Of Participants
40

France

Earliest CTIS Part Ii Submission Date
26-05-2025
Latest Decision Or Authorization Date
27-04-2026
Processing Time Days
336
Number Of Sites
5
Number Of Participants
40

Sites

Site Name
Les Hopitaux Universitaires De Strasbourg
Department Name
Service de pneumologie
Contact Person Name
Céline Mascaux
Site Name
Centre Hospitalier Universitaire De Rennes
Department Name
Service de pneumologie
Contact Person Name
Hervé Lena
Contact Person Email
herve.lena@chu-rennes.fr
Site Name
Centre Hospitalier Regional De Marseille
Department Name
Centre d'essais cliniques en cancérologie
Contact Person Name
Pascale Tomasini
Contact Person Email
pascale.tomasini@ap-hm.fr
Site Name
Institut Curie
Department Name
Département oncologie médicale
Contact Person Name
Nicolas Girard
Contact Person Email
nicolas.girard2@curie.fr
Site Name
Oncopole Claudius Regaud
Department Name
Département d'oncologie médicale
Contact Person Name
Julien Mazières

Sponsor

Primary sponsor

Full Name
Transgene
Organisation Type
Pharmaceutical company
Country Of Registered Address
France

Investigational products

Investigational Product Name
TG4070
Modality
Vaccine

Related trials

Other published trials that may interest you.